Skip to main content
Premium Trial:

Request an Annual Quote

DiaSorin Q3 Revenues Rise 51 Percent on Luminex Acquisition, Recovery of Non-COVID Test Sales

NEW YORK ─ DiaSorin said Thursday that its third quarter revenues rose 51 percent year over year, driven in part by a recovery in non-COVID-19 related test sales.

For the three months ended Sept. 30, the Saluggia, Italy-based company reported revenues of €343.5 million ($393.9 million) in revenues compared to €227.9 million in Q3 2020.

The firm said that its Q3 CLIA-test revenues rose 23 percent year over year to €140.4 million from €114.3 million. ELISA test revenues fell 11 percent year over year to €14.5 million from €16.3 million. Q3 molecular test revenues of €82.1 million were up 6 percent year over year from €77.8 million, and instruments sales and other revenues of €15.4 million dropped 21 percent year over year from €19.5 million. Luminex contributed €91.1 million to DiaSorin's Q3 revenues.

The company said its Q3 revenues grew 10 percent year over year excluding Luminex revenues.

DiaSorin completed the acquisition of Austin, Texas-based Luminex in July for $1.8 billion.

DiaSorin said in the recently completed quarter, it saw a strong recovery of non-COVID-19 related sales, which grew 8.4 percent year over year excluding Luminex revenues. The recovery of its non-COVID business was driven in particular by sales of latent tuberculosis tests as well as infectious disease, and Q3 sales of SARS-CoV-2 serology and molecular tests excluding Luminex revenues were €80.0 million, up 14 percent year over year compared to €70.4 million.

The company posted a Q3 net profit of €79.3 million compared to €67.8 million in Q3 2020.

Its Q3 R&D expenses rose 67 percent year over year to €20.8 million from €12.5 million, while its SG&A expenses increased 66 percent year over year to €85.9 million from €51.6 million.

DiaSorin said it had €327.7 million in cash and cash equivalents at the end of Q3.

For full-year 2021, the company expects year-over-year revenue growth of 40 percent at a constant exchange rate. Earlier this year, DiaSorin said it expected year-over-year revenue growth between 15 percent and 25 percent. In Q2, following the Luminex acquisition, DiaSorin said it anticipated 2021 revenues of approximately €1.2 billion.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.